Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

NCT01387230 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: GSK573719
DRUG: GSK573719
OTHER: Placebo

Sponsor

GlaxoSmithKline